H

HUTCHMED (China) Ltd
LSE:HCM

Watchlist Manager
HUTCHMED (China) Ltd
LSE:HCM
Watchlist
Price: 218 GBX 1.87% Market Closed
Market Cap: 1.9B GBX

Relative Value

The Relative Value of one HCM stock under the Base Case scenario is hidden GBX. Compared to the current market price of 218 GBX, HUTCHMED (China) Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HCM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
63
vs Industry
29
Median 3Y
4.3
Median 5Y
4.9
Industry
2.6
Forward
4.3
vs History
29
vs Industry
13
Median 3Y
5
Median 5Y
-8.4
Industry
21.4
Forward
29.6
vs History
vs Industry
26
Median 3Y
-8.5
Median 5Y
-10
Industry
16.4
vs History
vs Industry
26
Median 3Y
-46.1
Median 5Y
-20.4
Industry
22.8
vs History
87
vs Industry
21
Median 3Y
3.7
Median 5Y
3.7
Industry
2.2
vs History
84
vs Industry
38
Median 3Y
2.9
Median 5Y
3.3
Industry
2.9
Forward
2.2
vs History
80
vs Industry
28
Median 3Y
6.4
Median 5Y
7.8
Industry
5.5
vs History
vs Industry
3
Median 3Y
-23.2
Median 5Y
-20
Industry
13
Forward
-99.6
vs History
vs Industry
2
Median 3Y
-21.2
Median 5Y
-18.6
Industry
16.5
Forward
46
vs History
vs Industry
33
Median 3Y
-6.2
Median 5Y
-7.6
Industry
15.6
vs History
vs Industry
24
Median 3Y
-17.4
Median 5Y
-15.9
Industry
18.7
vs History
85
vs Industry
17
Median 3Y
5.1
Median 5Y
5.3
Industry
1.9

Multiples Across Competitors

HCM Competitors Multiples
HUTCHMED (China) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
HUTCHMED (China) Ltd
LSE:HCM
20.3B GBP 4.3 5.6 -177.6 -67.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.4 56.2 37.8 40.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
271B CHF 4.4 28.7 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
221.1B GBP 5.1 31.6 108.9 159.3
US
Merck & Co Inc
NYSE:MRK
278.1B USD 4.3 14.6 10.3 12.3
CH
Novartis AG
SIX:NOVN
218.9B CHF 4.9 19 12 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
HK
H
HUTCHMED (China) Ltd
LSE:HCM
Average P/E: 23
5.6
-18%
N/A
US
Eli Lilly and Co
NYSE:LLY
56.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
H
HUTCHMED (China) Ltd
LSE:HCM
Average EV/EBITDA: 440.1
Negative Multiple: -177.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
H
HUTCHMED (China) Ltd
LSE:HCM
Average EV/EBIT: 1 883.8
Negative Multiple: -67.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.3
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5